Literature DB >> 23081884

Sustained NMDA receptor hypofunction induces compromised neural systems integration and schizophrenia-like alterations in functional brain networks.

Neil Dawson1, Xiaolin Xiao, Martin McDonald, Desmond J Higham, Brian J Morris, Judith A Pratt.   

Abstract

Compromised functional integration between cerebral subsystems and dysfunctional brain network organization may underlie the neurocognitive deficits seen in psychiatric disorders. Applying topological measures from network science to brain imaging data allows the quantification of complex brain network connectivity. While this approach has recently been used to further elucidate the nature of brain dysfunction in schizophrenia, the value of applying this approach in preclinical models of psychiatric disease has not been recognized. For the first time, we apply both established and recently derived algorithms from network science (graph theory) to functional brain imaging data from rats treated subchronically with the N-methyl-D-aspartic acid (NMDA) receptor antagonist phencyclidine (PCP). We show that subchronic PCP treatment induces alterations in the global properties of functional brain networks akin to those reported in schizophrenia. Furthermore, we show that subchronic PCP treatment induces compromised functional integration between distributed neural systems, including between the prefrontal cortex and hippocampus, that have established roles in cognition through, in part, the promotion of thalamic dysconnectivity. We also show that subchronic PCP treatment promotes the functional disintegration of discrete cerebral subsystems and also alters the connectivity of neurotransmitter systems strongly implicated in schizophrenia. Therefore, we propose that sustained NMDA receptor hypofunction contributes to the pathophysiology of dysfunctional brain network organization in schizophrenia.

Entities:  

Keywords:  2-deoxyglucose autoradiographic imaging; graph theory; network science; phencyclidine

Mesh:

Substances:

Year:  2012        PMID: 23081884     DOI: 10.1093/cercor/bhs322

Source DB:  PubMed          Journal:  Cereb Cortex        ISSN: 1047-3211            Impact factor:   5.357


  24 in total

Review 1.  Functional magnetic resonance imaging of intrinsic brain networks for translational drug discovery.

Authors:  Jason Smucny; Korey P Wylie; Jason R Tregellas
Journal:  Trends Pharmacol Sci       Date:  2014-06-03       Impact factor: 14.819

Review 2.  Brain rhythms connect impaired inhibition to altered cognition in schizophrenia.

Authors:  Benjamin R Pittman-Polletta; Bernat Kocsis; Sujith Vijayan; Miles A Whittington; Nancy J Kopell
Journal:  Biol Psychiatry       Date:  2015-02-14       Impact factor: 13.382

Review 3.  The subchronic phencyclidine rat model: relevance for the assessment of novel therapeutics for cognitive impairment associated with schizophrenia.

Authors:  Sanna K Janhunen; Heta Svärd; John Talpos; Gaurav Kumar; Thomas Steckler; Niels Plath; Linda Lerdrup; Trine Ruby; Marie Haman; Roger Wyler; Theresa M Ballard
Journal:  Psychopharmacology (Berl)       Date:  2015-06-14       Impact factor: 4.530

Review 4.  Reviewing the ketamine model for schizophrenia.

Authors:  Joel Frohlich; John D Van Horn
Journal:  J Psychopharmacol       Date:  2013-11-20       Impact factor: 4.153

5.  Dysregulation of Epigenetic Control Contributes to Schizophrenia-Like Behavior in Ebp1+/- Mice.

Authors:  Inwoo Hwang; Jee-Yin Ahn
Journal:  Int J Mol Sci       Date:  2020-04-09       Impact factor: 5.923

Review 6.  Electrophysiological endophenotypes in rodent models of schizophrenia and psychosis.

Authors:  Andrew M Rosen; Timothy Spellman; Joshua A Gordon
Journal:  Biol Psychiatry       Date:  2015-03-27       Impact factor: 13.382

7.  Subanesthetic ketamine treatment promotes abnormal interactions between neural subsystems and alters the properties of functional brain networks.

Authors:  Neil Dawson; Martin McDonald; Desmond J Higham; Brian J Morris; Judith A Pratt
Journal:  Neuropsychopharmacology       Date:  2014-02-04       Impact factor: 7.853

8.  GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice.

Authors:  Lakshmi Rajagopal; Jeffrey S Burgdorf; Joseph R Moskal; Herbert Y Meltzer
Journal:  Behav Brain Res       Date:  2015-11-26       Impact factor: 3.332

9.  Disruption of social cognition in the sub-chronic PCP rat model of schizophrenia: Possible involvement of the endocannabinoid system.

Authors:  Alexandre Seillier; Andrea Giuffrida
Journal:  Eur Neuropsychopharmacol       Date:  2015-12-10       Impact factor: 4.600

Review 10.  Glutamate and dopamine in schizophrenia: an update for the 21st century.

Authors:  Oliver Howes; Rob McCutcheon; James Stone
Journal:  J Psychopharmacol       Date:  2015-01-13       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.